Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 9/20 | 0.54 |
| ▸ | REN | P00797 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | F2 | P00734 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | PEPD | P12955 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.54 |
| ▸ | HRH1 | P35367 | 1/20 | 0.54 |
| ▸ | THPO | P40225 | 1/20 | 0.54 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | PREP | P48147 | 1/20 | 0.45 |
| ▸ | FAP | Q12884 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6559375 | 1.00 | ACE (0.54) | ACERENLMNAKDM4EF2 | |
| SCHEMBL30140016 | 0.97 | ACE (0.51) | ACERENLMNAKDM4EF2 | |
| SCHEMBL29384148 | 0.95 | ACE (0.49) | ACERENLMNAKDM4EF2 | |
| SCHEMBL29836001 | 0.91 | ACE (0.46) | ACERENLMNAKDM4EF2 | |
| SCHEMBL30235083 | 0.89 | ACE (0.47) | ACERENLMNAKDM4EF2 | |
| SCHEMBL30446492 | 0.89 | ACE (0.56) | ACERENLMNAKDM4EF2 | |
| SCHEMBL30051675 | 0.89 | ACE (0.51) | ACERENLMNAKDM4EF2 | |
| SCHEMBL13402537 | 0.89 | FAP (0.45) | ACERENLMNAKDM4EF2 | |
| SCHEMBL31214680 | 0.87 | ACE (0.52) | ACERENLMNAKDM4EF2 | |
| SCHEMBL29470154 | 0.87 | ACE (0.52) | ACERENLMNAKDM4EF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122031713-A | Preparation method and application of linker medicine and antibody-medicine conjugate thereof | 乐普生物科技股份有限公司 | 2026-05-15 | — | — | CN | claimed |
| EP-4659764-A1 | LINKER DRUG, AND PREPARATION METHOD AND USE OF ANTIBODY-DRUG CONJUGATE THEREOF | Lepu Biopharma Co., Ltd. (CN) | 2025-12-10 | — | — | EP | claimed |
| EP-2694115-B1 | OPTICAL IMAGING PROBES | UNIV COURT UNIV OF EDINBURGH (GB) | 2024-10-23 | — | — | EP | claimed |
| WO-2024160176-A1 | LINKER DRUG, AND PREPARATION METHOD AND USE OF ANTIBODY-DRUG CONJUGATE THEREOF | 上海美雅珂生物技术有限责任公司 | 2024-08-08 | — | — | WO | claimed |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | NOVARTIS AG (CH) | 2023-12-14 | — | — | US | claimed |
| US-20230374112-A1 | Bioactive Collagen Peptides, Method Of Production Thereof, And Use Thereof | BDC CAPITAL INC. (CA) | 2023-11-23 | — | — | US | claimed |
| CN-115433752-A | Method for generating protein with arbitrary site-directed modification and calibration product | 苏州有诺真生物科技有限公司 | 2022-12-06 | — | — | CN | claimed |
| CN-112898375-B | Novel inhibitory peptide of bacillus-derived alkaline protease | 天津科技大学 | 2022-11-01 | — | — | CN | claimed |
| WO-2022067445-A1 | BIOACTIVE COLLAGEN PEPTIDES, METHOD OF PRODUCTION THEREOF, AND USE THEREOF | CORPORATION GENACOL CANADA INC. (CA) | 2022-04-07 | — | — | WO | claimed |
| CN-112235792-B | Multi-type terminal access and switching authentication method, system, equipment and application | 西安电子科技大学 | 2022-03-11 | — | — | CN | claimed |
| CN-122075733-A | Preparation method and application of linker medicine and antibody-medicine conjugate thereof | — | 2026-05-26 | — | — | CN | disclosed |
| CN-122031713-A | Preparation method and application of linker medicine and antibody-medicine conjugate thereof | 乐普生物科技股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-12622975-B2 | Peptide-conjugated prodrugs | BRANDEIS UNIVERSITY (US) | 2026-05-12 | — | — | US | disclosed |
| US-12617872-B2 | Heterodimeric human IgG1 polypeptides with isoelectric point modifications | XENCOR, INC. (US) | 2026-05-05 | — | — | US | disclosed |
| US-12605451-B2 | Targeted plasma protein degradation | NOVARTIS AG (CH) | 2026-04-21 | — | — | US | disclosed |
| US-4665053-A | HYDROPHOBIC CARBOXYLIC MODIFIER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1987-05-12 | — | — | US | disclosed |
| EP-0126009-B1 | PEPTIDE DERIVATIVES, THEIR PREPARATION AND USE AS ELASTASE INHIBITORS | Etablissement Public dit: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1987-01-14 | — | — | EP | disclosed |
| EP-0195212-A2 | Novel peptidase inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1986-09-24 | — | — | EP | disclosed |
| US-4554100-A | ENZYME INHIBITORS | SPOFA, SPOJENE PODNIKY PRO ZDRAVOTNICKOU VYROBU (CS) | 1985-11-19 | — | — | US | disclosed |
| EP-0126009-A1 | Peptide derivatives, their preparation and use as elastase inhibitors | Etablissement Public dit: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1984-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12622975-B2 | Peptide-conjugated prodrugs | PEPD, PAM, VIP | ACE 1190/4885REN 2773/4885LMNA 1538/4885 |
| US-12617872-B2 | Heterodimeric human IgG1 polypeptides with isoelectric point modifications | IGLV6-57, CHAMP1, FCGRT | ACE 4507/4885REN 3595/4885LMNA 4137/4885 |
| US-12605451-B2 | Targeted plasma protein degradation | M6PR, ASGR1, IGF2R | ACE 857/4885REN 3069/4885LMNA 1051/4885 |
| US-20230398224-A1 | TARGETED PLASMA PROTEIN DEGRADATION | M6PR, ASGR1, IGF2R | ACE 1723/4885REN 3049/4885LMNA 2133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.